RELAPSED/REFRACTORY NON-HODGKIN LYMPHOMA
Clinical trials for RELAPSED/REFRACTORY NON-HODGKIN LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new RELAPSED/REFRACTORY NON-HODGKIN LYMPHOMA trials appear
Sign up with your email to follow new studies for RELAPSED/REFRACTORY NON-HODGKIN LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Engineered immune cells offer new hope for Hard-to-Treat blood cancers
Disease control Recruiting nowThis study tests a new treatment called Talikabtagene autoleucel (NexCAR19) for adults with certain blood cancers that have come back or not responded to standard therapy. The treatment uses a patient's own immune cells, which are modified in a lab to better recognize and attack …
Matched conditions: RELAPSED/REFRACTORY NON-HODGKIN LYMPHOMA
Phase: PHASE2, PHASE3 • Sponsor: Health Institutes of Turkey • Aim: Disease control
Last updated May 17, 2026 11:39 UTC
-
New hope for tough lymphoma: experimental drug targets cancer from inside
Disease control Recruiting nowThis study tests a new experimental drug, BMS-986458, in people with non-Hodgkin lymphoma that has returned or not responded to prior therapies. The drug works by breaking down a protein inside cancer cells that helps them grow. Researchers will test it alone and with other lymph…
Matched conditions: RELAPSED/REFRACTORY NON-HODGKIN LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated May 15, 2026 11:54 UTC